Xpovio (selinexor) combined with Kyprolis (carfilzomib) and low-dose dexamethasone leads to strong and durable responses in heavily pretreated multiple myeloma patients, results from a Phase 1/2b trial show. The study, “Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients,” was published in the British Journal of Cancer. Xpovio, developed by Karyopharm Therapeutics, is an oral inhibitor of the XPO1 protein and prevents tumor suppressor proteins from leaving the cell nucleus. This leads to…
You must be logged in to read/download the full post.
The post Xpovio-Kyprolis Combo Shows Good Response in Hard-to-treat Myeloma appeared first on BioNewsFeeds.